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The forkhead protein, FOXA1, is a critical interacting partner of the nuclear hormone
receptors, oestrogen receptor-α (ER) and androgen receptor (AR), which are major drivers
of the two most common cancers, namely breast and prostate cancer. Over the past few
years, progress has been made in our understanding of how FOXA1 influences nuclear
receptor function, with both common and distinct roles in the regulation of ER or AR.
Recently, another level of regulation has been described, with the discovery that FOXA1
is mutated in 1.8% of breast and 3–5% prostate cancers. In addition, a subset of both
cancer types exhibit amplification of the genomic region encompassing the FOXA1 gene.
Furthermore, there is evidence of somatic changes that influence the DNA sequence
under FOXA1 binding regions, which may indirectly influence FOXA1-mediated regulation
of ER and AR activity. These recent observations provide insight into the heterogeneity
observed in ER and AR driven cancers.
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Hormone-dependent breast and prostate cancers, constitute a
major global cancer burden, in females and males, respectively,
with a combined total of nearly 2.3 million new cases each year
(Ferlay et al., 2010). In a large proportion of these cancers, the
nuclear receptors AR in prostate cancer and ER in breast cancer,
drive tumor growth in response to activation by their natural lig-
ands, testosterone and oestrogen. A protein commonly expressed
in hormonally-driven cancers is the transcription factor FOXA1
which appears to be intrinsic to tumor development in both
breast and prostate cancer. Recent discoveries of amplification of
the FOXA1 locus, mutations within the FOXA1 gene and muta-
tions in the genomic regions FOXA1 occupies, are shedding light
on mechanisms that perturb FOXA1 function and ultimately
ER/AR activity.
FOXA1 IS CRITICAL FOR AR AND ER FUNCTION IN CANCER
FOXA1 is one of three members of the highly related FOXA
family. All forkhead proteins contain a “winged helix” DNA
binding or forkhead domain, consisting of three α-helices, three
β-sheets, and two loops or wings (Hannenhalli and Kaestner,
2009). The crystal structure of the forkhead domain shows that
FOXA1 sits in the major groove of DNA with the loops mak-
ing site-specific DNA contacts in a manner that closely resembles
linker histone (Clark et al., 1993). FOXA proteins are often
termed “pioneer factors” because they are able to bind to highly
compacted, or “closed,” chromatin (Cirillo et al., 1998) and
through their C-terminal domain make these genomic regions
more accessible to other transcription factors (Cirillo et al., 2002)
(Figure 1A).
Like other forkhead proteins, FOXA1 plays a key role in devel-
opment, chiefly the lung and liver (Wan et al., 2004; Lee et al.,
2005). With regards to the development of mammary glands
and prostate rudiment, the FoxA1−/− mouse shows a normal
phenotype at birth, but neither tissue is able to respond to hor-
mone induction through AR and ER during puberty which results
in ductal branching and epithelial cell maturation (Gao et al.,
2005; Bernardo et al., 2010). FOXA1’s direct interaction with AR
and ER was first shown at the single locus level, probasin and
PSA for AR (Gao et al., 2003), and vitellogenin for ER (Robyr
et al., 2000). Later genome wide chromatin-immunoprecipitation
experiments (ChIP-seq) for AR, ER, and FOXA1 in breast and
prostate cancer cell lines and primary tumor tissue revealed a
high level of co-occupancy between this pioneer factor and its
respective nuclear receptor, presumably mediated by the forkhead
motif found at AR and ER binding events (Carroll et al., 2006;
Wang et al., 2007; Jia et al., 2008; Hurtado et al., 2011). Loss of
FOXA1 expression by targeted siRNA transfection in breast and
prostate cancer cell lines results in reduction of growth suggest-
ing an essential role in the proliferation of both cancers (Hurtado
et al., 2011; Robinson et al., 2011; Zhang et al., 2011) yet the
mechanistic role for FOXA1 in ER and AR biology appears to be
different.
FOXA1 is required for global ER binding in the MCF7 breast
cancer cell line and ER occupancy at >90% of binding events is
reduced when FOXA1 is silenced, which correlates with a global
loss in the accessibility of chromatin (Hurtado et al., 2011). This
loss of ER binding blocks ER-mediated gene expression and pro-
liferation. In prostate cancer, however, when FOXA1 is lost, AR
can still bind to chromatin and in fact occupies new binding
sites which are coupled to changes in its’ transcriptional targets
(Sahu et al., 2011; Wang et al., 2011). Moreover, FOXA1 expres-
sion levels have opposing effects on patient outcome in breast
and prostate cancer. In breast cancer, FOXA1 has been shown in
multiple studies to be an independent marker for good outcome
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FIGURE 1 | Interactions between FOXA1 and the hormone receptors
AR and ER. (A) WT FOXA1 is able to bind to condensed chromatin
and make this region more accessible to AR and ER which bind to
DNA after hormone stimulation. (B) Various genomic alterations can
occur to FOXA1 such as amplification of the FOXA1 locus, mutations
to the coding sequence of FOXA1 or single nucleotide variants (SNVs)
in the forkhead motif found at most FOXA1 binding events. This
could results in an increase, decrease, or change in position of
FOXA1 binding which in turn could affect AR and ER in the ways
described above.
(Badve et al., 2007; Hisamatsu et al., 2012); most probably
because the presence of FOXA1 indicates a functional ER com-
plex which will respond well to anti-oestrogen compounds such
as Tamoxifen. Conversely, in prostate cancer, high levels of FOXA1
correlate with poor prognosis (Sahu et al., 2011; Gerhardt et al.,
2012). FOXA1 and AR levels correlate with one another, sug-
gesting that an overactive AR transcriptional complex may be
present in these tumors to overcome androgen deprivation more
effectively. Interestingly, there is evidence of a common reliance
in late stage disease as FOXA1 levels are high in both breast and
prostate cancer metastases (Jain et al., 2011; Ross-Innes et al.,
2012).
ADVANCES IN DNA SEQUENCING TECHNOLOGIES
Genomic sequencing capacity has increased at an extraordi-
nary rate, enhancing our ability to interrogate genetic changes
and global genomic patterns. Since the first cancer genome was
sequenced in 2008 (Ley et al., 2008), there have been numer-
ous other sequencing studies with increasing numbers of tumors
at greater genome coverage, made possible by improvements
in DNA sequencing output coupled with a large decrease in
cost (Meyerson et al., 2010). Whole exome- and whole-genome
sequencing allow unbiased sequencing of cancer vs. normal
exons or entire genomes to look for cancer specific somatic
mutations and chromosomal rearrangements, amplifications or
Frontiers in Oncology | Molecular and Cellular Oncology February 2013 | Volume 3 | Article 20 | 2
Robinson et al. FOXA1 mutations in hormone-dependent cancers
deletions. All the studies in this review have a minimum of
30-fold coverage over each gene, meaning it is possible to detect
mutations which may only occur in a subset of cells in the
tumor. Transcriptomic data from RNA-seq is also being mined
to assess for changes in transcript expression levels that are influ-
enced by these mutations. Integration of these genetic alterations
will provide insight into the events that contribute to tumor
progression.
MUTATIONS IN PROSTATE CANCER
Unlike breast cancer, prostate cancer patients cannot be prognos-
tically stratified based on mRNA expression profiles, therefore it
is critical that genomic contributors to outcome are defined. Two
large prostate cancer sequencing papers recently reported that
FOXA1 mutations occur in 3.4–5.2% of tumors (Barbieri et al.,
2012; Grasso et al., 2012). This finding has not been observed in
any of the previous prostate cancer sequencing studies, probably
because those earlier studies either lacked the number of sam-
ples or the sequencing depth required to detect variants that were
present at low frequency (Taylor et al., 2010; Berger et al., 2011;
Kumar et al., 2011).
The first study to report mutations in FOXA1 performed
whole exome sequencing on 112 treatment-naive prostate ade-
nocarcinomas as well as RNA-seq analysis on transcripts from
63 tumors (Barbieri et al., 2012). They found 12 genes which
were significantly mutated, all of which were highly expressed
in prostate cancer. A total of eight non-silent mutations in
FOXA1 were identified clustered around the forkhead DNA bind-
ing domain (Table 1). Grasso et al., independently discovered
by exome sequencing, FOXA1 to be mutated in a single tumor
from their cohort of 11 high-grade localized prostate cancers
but in none of their 50 metastatic castrate resistant prostate
cancers (CRPC) obtained from rapid autopsies (Grasso et al.,
2012). The mutation was a 2 bp insertion which resulted in a
frame shift (S453fs) and two more frame shift mutations were
detected in FOXA1 from exome sequencing of 11 prostate can-
cer cell lines (P358fs in hormone-sensitive LAPC-4 and A339fs
in castrate resistance model DU-145). Based on this initial
observation, a total of 101 localized prostate cancers and 46
CRPCs were subsequently targeted sequenced, within which five
harbored mutations in FOXA1. Only one CRPC sample har-
bored a FOXA1 mutation which was isolated from a patient
included in the initial exome study, but the DNA used in the
targeted sequencing was obtained from a different site suggest-
ing the FOXA1 mutation was a divergent event not seen in the
primary tumor.
MUTATIONS IN BREAST CANCER
Six major breast cancer genomic studies were published in 2012
which utilize high-throughput sequencing techniques to tease
Table 1 | FOXA1 mutations in breast and prostate cancer.
Cancer Sequencing method Amino acid Type of mutation Position in FoxA1 Occurrence References
change (fraction of patients)
Breast Whole exome A153V Missense N-terminal 1/507 TCGA, 2012
S194fs Frame shift Forkhead domain 1/507
H247Y Missense Forkhead domain 1/507
D226N Missense Forkhead domain 1/507
S250F Missense Forkhead domain 1/507
I176M Missense Forkhead domain 2/507
Prostate Whole exome F400I Missense C-Terminal TA domain 1/46 - CRPC Grasso et al., 2012
D226N* Missense Forkhead domain 1/111 Barbieri et al., 2012
A232V Missense Forkhead domain 1/111
M253R* Missense Forkhead domain 1/111
M253K* Missense Forkhead domain 1/111
RNA-seq M253R* Missense Forkhead domain 1/41 Barbieri et al., 2012
M253K* Missense Forkhead domain 1/41
D226N* Missense Forkhead domain 1/41
D226Y Missense Forkhead domain 1/41
Sanger G87R Missense N-Terminal TA domain 1/101 Grasso et al., 2012
L388M Missense C-Terminal TA domain 1/101
S453fs Frame shift C-Terminal TA domain 1/101
L455M Missense C-Terminal TA domain 1/101
P358fs Frame shift C-Terminal TA domain N/A - LAPC-4 Cell Line
A339fs Frame shift C-Terminal TA domain N/A - DU-145 Cell Line
TA, transactivation; CRPC, castrate resistant prostate cancer. Unless otherwise stated sample was extracted from a primary tumor. Barbieri et al. used two
independent cohorts of patients for exome sequencing and RNA-seq therefore mutations seen by both techniques were identified in two independent patients
(indicated by *). D226N is the only mutation seen in both breast and prostate cancer.
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apart the important mutations, chromosomal rearrangements,
and DNA methylation changes which occur in breast cancer.
The findings have reinforced the role of known breast cancer
driver genes such as TP53, ERBB2, (HER2) and PIK3CA and
led to the discovery of a plethora of novel oncogenic muta-
tions, including FOXA1 in The Cancer Genome Atlas (TCGA)
study (TCGA, 2012). The TCGA study assessed a total of 825
patients to ranging extents on six different platforms, includ-
ing exome sequencing of 507 tumors and matched normal
DNA. They identified eight tumors with mutations in FOXA1
(Table 1) placing it on the cusp of being a significantly mutated
gene as determined by the MuSiC package (Dees et al., 2012).
In total, they found 35 genes significantly mutated and two
genes at borderline significance (FOXA1 and CTCF). This raises
an important point because none of the other four studies
which carried out whole-exome or whole-genome sequencing
reported any FOXA1 mutations (Banerji et al., 2012; Ellis et al.,
2012; Shah et al., 2012; Stephens et al., 2012). These studies
all had smaller sample sizes (ranging from 77 to 108 sam-
ples), which would not have been sufficient to detect FOXA1
mutants which, based on the TCGA study, only occur in 1.8%
patients. Furthermore, one of the studies (Shah et al., 2012) used
a selected population of exclusively ER-PR-HER2-patients and
all FOXA1 mutations in the TCGA study were found in ER+
tumors.
Gene expression profiling was applied to the eight tumors
identified with FOXA1 mutations and the majority were lumi-
nal A tumors (5/8) and the remainder were luminal B (2/8) and
HER2 (1/8). Another ER interacting partner, GATA3, was found
to be highly mutated in all the studies (10.8% of breast cancers
in TCGA study), although GATA3 and FOXA1 mutations were
mutually exclusive.
FOXA1 COPY NUMBER ALTERATIONS
The genomic region encompassing the FOXA1 gene (14q21.1)
is amplified in a range of cancers (Yasui et al., 2001; Lin et al.,
2002; Nucera et al., 2009; Deutsch et al., 2012) and there is
increasing evidence this also occurs in prostate and breast can-
cer. FOXA1 amplification in prostate cancer was identified from
the profiling of eight systemic metastatic tumors in a range of
organs from six unrelated patients. Focal amplification of 14q21.1
was found in three independent lesions isolated from a single
patient, suggesting amplification of the FOXA1 genomic region is
an early event in progression of this tumor (Robbins et al., 2011).
Furthermore, there is evidence of amplification of FOXA1 in a
lymph node metastasis in an independent cohort (Grasso et al.,
2012).
In breast cancer, the TCGA study reported that 1% of the
773 breast cancer tumors tested have focal amplification of the
region containing the FOXA1 genomic locus, consisting of six
ER+ and two HER2 tumors (TCGA, 2012). However, there was
no evidence of amplification of this region in the larger study pub-
lished by Curtis et al. which categorized 1992 breast cancers on the
basis of copy number changes and mRNA profiles (Curtis et al.,
2012) even though this study generally correlates well with the
TCGA data.
SEQUENCE CHANGES OF THE DNA BINDING MOTIF
MODULATE FOXA1 BINDING
FOXA1 binds primarily at enhancer regions of genes through-
out the genome most of which contain the consensus forkhead
(FKH) motif. Recently, a report described that single nucleotide
polymorphisms (SNPs) in the binding sites of forkhead proteins
can not only modulate FOXA1 binding to the chromatin, but lead
to changes in expression of adjacent genes (Cowper-Sal Lari et al.,
2012). Cowper-Sal Lari et al. developed a novel computational
method called intragenomic replicates (IGR) to accurately predict
the affinity of a transcription factor for the reference and vari-
ant alleles of a SNP in a given genomic context. Using ChIP-seq
data for FOXA1 they are able to measure the affinity of FOXA1
for a given DNA sequence. They demonstrate that FOXA1 has a
high affinity for DNA with a forkhead motif comprising of a C
at position 8 combined with an A at position 6, a sequence com-
bination which has six times greater affinity than when the base
at position 6 is a G. This emphasizes the concept that transcrip-
tion factor binding is not a binary event and that quantitative
differences in binding can have a profound effect on activity. In
the example provided, a base pair change at position 8 of the
FKH motif occurs 18 kb upstream of the TOX3 gene with the
variant SNP causing an increase in FOXA1 binding and a con-
comitant decrease in expression of TOX3, leading to increased cell
proliferation.
Another report from the Lupien lab (Zhang et al., 2012) shows
functional analysis of a SNP present in a prostate cancer risk
locus which changes the tenth position of the FKH DNA motif.
Using an in vitro reporter assay they show a 2-fold decrease in
FOXA1 binding to the variant allele compared to the reference
allele, resulting in a 50% increase in luciferase activity. Further
supporting this work, a subset of SNPs occurring in hepatocel-
lular carcinoma (HCC) can alter the binding of FOXA2, another
forkhead protein, resulting in altered expression, a finding that
was confirmed in patient samples on several target genes (Li et al.,
2012). These examples point to the role that genetic variants can
play on FOXA1-DNA interactions and the physiological impact
that can have by changing expression levels of key target genes.
FUNCTIONAL RELEVANCE OF FOXA1 ABERRATIONS
Mutations in the coding sequence of FOXA1 occur in two clusters
(Table 1), either in or around the forkhead DNA binding domain
or in the C-terminal transactivation domain. Two mutational
hotspots are present in the forkhead domain; position D226,
mutated in a total of five patients, across both breast and prostate
cancer, and position M253, mutated in four prostate tumors.
Experimental modeling of these mutations within the DNA bind-
ing domain is yet to be conducted therefore it is not known
whether they increase or perturb FOXA1 binding. However, pre-
vious studies on FOXA1 provide clues as to what may be the
downstream effects of these changes.
In breast cancer if these mutations do diminish the binding
capability of FOXA1, ER’s dependency upon FOXA1 for bind-
ing (Hurtado et al., 2011) suggests that these tumors may have
evolved to become independent of oestrogen for growth. These
tumors would likely bemore aggressive as they would not respond
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to standard hormonal therapies (Figure 1B). On the contrary, in
prostate cancer, as AR is still able to bind in the absence of FOXA1,
a mutation in FOXA1 which inhibits its DNA binding capacity
may not inhibit AR binding, but could instead alter its binding
profile and transcriptional targets (Sahu et al., 2011; Wang et al.,
2011).
Alternatively, mutations within the forkhead domain could
affect FOXA1’s affinity for its canonical binding site, potentially
resulting in binding to new genomic locations, which may result
in substantial effects on the transcriptional program within that
tumor, for example FOXA1’s recruitment to novel sites in the
CRPC cell line LNCaP-abl, allows it to become androgen inde-
pendent (Zhang et al., 2011). FOXA1-DNA associations may also
be affected on a site by site basis, due to SNPs occurring in FOXA1
binding sites (Cowper-Sal Lari et al., 2012). Insights into how
changes in specific forkhead motifs can affect transcription factor
recruitment at that site, as well as downstream gene expression
changes, could prove to be essential in determining the “most
important” FOXA1 binding events in cancer.
Grasso et al. conducted the first set of functional analysis of the
N- and C-terminal mutations detected, by creating prostate can-
cer cell lines stably expressing five of the mutants (Grasso et al.,
2012). In these preliminary experiments, only one of the muta-
tions, L388M, caused a growth increase over wild type (WT)
FOXA1 overexpression. AR-FOXA1 interaction was still impor-
tant in this mutant cell line as it remained reliant upon androgen
for growth. The S453fs mutant and WT FOXA1 were overex-
pressed in xenograft tumors which resulted in significantly larger
tumors, but the mutation posed no growth advantage over WT.
Even though the authors themselves express the need for fur-
ther characterization of the mutations, we could speculate that
this cluster of mutations within the C-terminus may change the
constituents of the FOXA1 complex. In CRPC, AR splice vari-
ants are expressed which could preferentially bind to FOXA1
mutants, a feasible theory as these splice events often occur in the
hinge domain of AR, which constitutes its’ interaction point with
FOXA1 (Wang et al., 2011).
Finally, FOXA1 binding may be increased due to a mutation
stabilizing the protein via changes in its’ DNA interaction affinity
or through copy number gains in the FOXA1 locus resulting in
elevated protein levels. In prostate cancer, FOXA1 genomic locus
amplification was only observed in metastatic samples (Robbins
et al., 2011; Grasso et al., 2012), which correlates with the obser-
vation of elevated FOXA1 staining in metastases and high grade
tumors (Gerhardt et al., 2012). Increased levels of WT FOXA1
significantly increase prostate cancer proliferation and the size of
xenograft tumors (Grasso et al., 2012), possibly due to increased
AR-mediated growth. In breast cancer, however, high levels of
FOXA1 are a marker of good prognosis (Badve et al., 2007;
Hisamatsu et al., 2012) possibly because elevated FOXA1 in breast
cancer engenders a greater reliance upon ligand-dependent ER
activity to drive tumorigenesis, which in turn would generate
hypersensitivity to anti-oestrogen therapies. This theory suggests
that breast tumors with amplification of FOXA1 would be more
responsive to treatment and the patients would have a better
prognosis (Figure 1B).
Reliance upon ligands for nuclear receptor activation could
be a fundamental difference between breast and prostate cancer
and may explain why the two hormone receptors respond differ-
ently to gain and loss of FOXA1. If AR driven prostate cancers
readily acquire ligand independence, elevated FOXA1-AR activity
would be an advantage to the tumor, supporting the observa-
tion that high FOXA1 is a marker of poor patient outcome. In
contrast, breast cancers may retain ligand dependence for longer,
permitting the paradoxical acquisition of both elevated estrogen-
mediated ER-FOXA1 activity and increased sensitivity to drugs
that block this pathway. It will be critical to determine the key ER
and AR target gene changes at high and low FOXA1 levels and any
differences in the associated AR/ER protein complexes.
CONCLUSION
It is evident that FOXA1 can be regulated at a genomic level either
through somatic mutations, genomic amplification, or changes to
the sequence within binding regions. Due to the lack of current
follow up and low frequency of events there is no current indi-
cation on how these changes affect patient outcome. As such, it
is important to collect functional data on the genomic changes
observed in breast and prostate cancer.
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